Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
Recruiting now
Conditions studied: Chemotherapy-induced Peripheral Neuropathy
In brief
Investigation of which patients treated with paclitaxel have an increased risk of developing peripheral neuropathy.
Key facts
- Study ID
- NCT06430814
- Run by
- University of Southern Denmark
- People needed
- 188
- Starts
- 2024-10-10
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2025-09-02
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Age > 18 years
- Willing to give informed consent
- Scheduled to receive neo-adjuvant or adjuvant paclitaxel treatment
- Able to speak and understand Danish
- Diagnosed with breast cancer
- Paclitaxel naïve patients
You may not qualify if…
- Neurodegenerative diseases (e.g., neuropathy from another cause, previous apoplexy, disc herniation
- Type 1 or 2 diabetes
- Pregnant
- Breastfeeding
- Relapse of cancer diagnosis
- Diagnosed with human immunodeficiency virus (HIV)
- Participation in other clinical trials where the dose of paclitaxel is changed, or the aim is to prevent neuropathic pain or decrease NFL level (except if the intervention is to use cooling gloves).
- Previous treatment with neurotoxic chemotherapy
- Chronic pain from another cause
- Metastatic cancer
Where it is running
- Odense University Hospital — Odense, Denmark (enrolling)
- University Hospital of Southern Denmark, Sønderborg — Sønderborg, Denmark (enrolling)
- University Hospital of Southern Denmark, Vejle — Vejle, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.